×

Photodynamic therapy treatment for eye disease

  • US 7,320,786 B2
  • Filed: 12/07/2005
  • Issued: 01/22/2008
  • Est. Priority Date: 01/12/2000
  • Status: Expired due to Fees
First Claim
Patent Images

1. A method of treating neovascular disease of the eye, comprising:

  • administering a conjugate to target neovascular tissue of the eye comprising;

    a photosensitizing compound selected from the group consisting of chlorines, bacteriochlorophylls, phthalocyanines, porphyrins, purpurins, merocyanines, psoralens, porfimer sodium, delta-aminolevulinic acid protoporphyrin, indocyanine green, benzoporphyrin, methylene blue, toluidine blue, texaphyrins, pyropheophorbide compounds, and verteporfin; and

    a targeting moiety that selectively binds to abnormal endothelium, wherein the targeting moiety consists of an antibody or an antibody fragment thereof that binds to a VEGF receptor;

    allowing sufficient time for the conjugate to clear from non-targeted tissue of the eye; and

    illuminating the eye with a light having a wave length or waveband absorbed by the targeted photosensitizing compound to activate the photosensitizing compound, andwherein the light has a combination of an intensity of light of less than 500 mW/cm2 and a duration of illumination of about 4 minutes to produce a total fluence of light irradiation from between about 30 J/cm2 to about 25,000 J/cm2 which destroys the targeted neovascular tissue while the non-targeted tissue remains undamaged.

View all claims
  • 3 Assignments
Timeline View
Assignment View
    ×
    ×